Alteration of Transthyretin and Thyroxine-Binding Globulin in Major Depressive Disorder: Multiple Reaction Monitoring-Based Proteomic Analysis
Background: Major depressive disorder (MDD), common mental disorder, lacks objective diagnostic and prognosis biomarkers. The objective of this study was to perform proteomic analysis to identify proteins with changed expression levels after antidepressant treatment and investigate differences in protein expression between MDD patients and healthy individuals.
Methods: A total of 111 proteins obtained from literature review were subjected to multiple reaction monitoring (MRM)-based protein quantitation. Finally, seven proteins were quantified for plasma specimens of 10 healthy controls and 78 MDD patients (those at baseline and at 6 weeks after antidepressant treatment of either selective serotonin reuptake inhibitors (SSRIs) or mirtazapine).
Results: Among 78 MDD patients, 35 patients were treated with SSRIs and 43 patients were treated with mirtazapine. Nineteen (54.3%) and 16 (37.2%) patients responded to SSRIs and mirtazapine, respectively. Comparing MDD patients with healthy individuals, alteration of transthyretin was observed in MDD (p = 0.026). A few differences were observed in protein levels related to SSRIs treatment, although they were not statistically significant. Plasma thyroxine-binding globulin (TBG) was different between before and after mirtazapine treatment only in responders (p = 0.007).
Conclusions: In proteomic analysis of plasma specimens from MDD patients, transthyretin and TBG levels were altered in MDD and changed after antidepressant treatment.
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Additional file 1: Table S1. 111 candidate proteins for proteomic analysis.
Posted 06 Jan, 2021
On 15 Jan, 2021
On 05 Jan, 2021
On 22 Dec, 2020
On 22 Dec, 2020
On 22 Dec, 2020
On 29 Nov, 2020
On 29 Nov, 2020
On 29 Nov, 2020
On 29 Nov, 2020
On 04 Nov, 2020
Received 09 Oct, 2020
On 25 Sep, 2020
Invitations sent on 24 Sep, 2020
On 12 Sep, 2020
On 11 Sep, 2020
On 07 Sep, 2020
On 31 Aug, 2020
Alteration of Transthyretin and Thyroxine-Binding Globulin in Major Depressive Disorder: Multiple Reaction Monitoring-Based Proteomic Analysis
Posted 06 Jan, 2021
On 15 Jan, 2021
On 05 Jan, 2021
On 22 Dec, 2020
On 22 Dec, 2020
On 22 Dec, 2020
On 29 Nov, 2020
On 29 Nov, 2020
On 29 Nov, 2020
On 29 Nov, 2020
On 04 Nov, 2020
Received 09 Oct, 2020
On 25 Sep, 2020
Invitations sent on 24 Sep, 2020
On 12 Sep, 2020
On 11 Sep, 2020
On 07 Sep, 2020
On 31 Aug, 2020
Background: Major depressive disorder (MDD), common mental disorder, lacks objective diagnostic and prognosis biomarkers. The objective of this study was to perform proteomic analysis to identify proteins with changed expression levels after antidepressant treatment and investigate differences in protein expression between MDD patients and healthy individuals.
Methods: A total of 111 proteins obtained from literature review were subjected to multiple reaction monitoring (MRM)-based protein quantitation. Finally, seven proteins were quantified for plasma specimens of 10 healthy controls and 78 MDD patients (those at baseline and at 6 weeks after antidepressant treatment of either selective serotonin reuptake inhibitors (SSRIs) or mirtazapine).
Results: Among 78 MDD patients, 35 patients were treated with SSRIs and 43 patients were treated with mirtazapine. Nineteen (54.3%) and 16 (37.2%) patients responded to SSRIs and mirtazapine, respectively. Comparing MDD patients with healthy individuals, alteration of transthyretin was observed in MDD (p = 0.026). A few differences were observed in protein levels related to SSRIs treatment, although they were not statistically significant. Plasma thyroxine-binding globulin (TBG) was different between before and after mirtazapine treatment only in responders (p = 0.007).
Conclusions: In proteomic analysis of plasma specimens from MDD patients, transthyretin and TBG levels were altered in MDD and changed after antidepressant treatment.
Figure 1
Figure 2